Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma

Nozomi Niitsu, Masataka Okamoto, Sadao Aoki, Hirokazu Okumura, Tadashi Yoshino, Ikuo Miura, Masami Hirano

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Our aim was to study the efficacy of the addition of etoposide and bleomycin to a [cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisone (PDN)] CHOP-like regimen for the treatment of aggressive lymphoma. The CyclOBEAP regimen was administered over a total period of 12 weeks. Doxorubicin, 50 mg/m2, was given every 2 weeks in combination with either cyclophosphamide, 1,000 mg/m2, (weeks 1, 5, 9) or etoposide, 70 mg/m2 qd ×4 (weeks 3, 7, 11). During the alternate weeks, non-myelosuppressive vincristine, 1.4 mg/m2 (maximum, 2.0 mg/ body), was given either with bleomycin, 10 mg/m2 (weeks 2, 6, 10), or alone (weeks 4,8,12). Prednisolone, 40 mg/m2, was administered daily for 14 days during weeks 1-2, 5-6, and 9-10. There were 121 eligible patients and median age of 51 years. A complete response was achieved in 106 patients (88%) and a partial response in 11 patients. The 5-year overall survival (OS) rate was 72% and progression-free survival (PFS) rate was 62%. When the patients were divided according to the International Prognostic Index (IPI), the 5-year OS and PFS rates did not significantly differ among risk groups. When the patients with DLBCL were divided according to the IPI, the 5-year OS and PFS rates also did not significantly differ. World Health Organization (WHO) grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 13 patients. No treatment-related deaths were observed. The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma. We will perform a prospective study of CyclOBEAP regimen combined with rituximab and test its safety and efficacy.

Original languageEnglish
Pages (from-to)374-380
Number of pages7
JournalAnnals of Hematology
Volume85
Issue number6
DOIs
Publication statusPublished - Jun 2006
Externally publishedYes

Fingerprint

Bleomycin
Etoposide
Lymphoma
Survival Rate
Disease-Free Survival
Vincristine
Doxorubicin
Cyclophosphamide
Survival
Therapeutics
Prednisone
Prednisolone
Neutropenia
Thrombocytopenia
Prospective Studies
Safety

Keywords

  • Aggressive lymphoma
  • CyclOBEAP
  • Diffuse large B-cell lymphoma
  • International prognostic index

ASJC Scopus subject areas

  • Hematology

Cite this

Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. / Niitsu, Nozomi; Okamoto, Masataka; Aoki, Sadao; Okumura, Hirokazu; Yoshino, Tadashi; Miura, Ikuo; Hirano, Masami.

In: Annals of Hematology, Vol. 85, No. 6, 06.2006, p. 374-380.

Research output: Contribution to journalArticle

Niitsu, Nozomi ; Okamoto, Masataka ; Aoki, Sadao ; Okumura, Hirokazu ; Yoshino, Tadashi ; Miura, Ikuo ; Hirano, Masami. / Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. In: Annals of Hematology. 2006 ; Vol. 85, No. 6. pp. 374-380.
@article{35c2bdcc2a024a8982086092616838c6,
title = "Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma",
abstract = "Our aim was to study the efficacy of the addition of etoposide and bleomycin to a [cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisone (PDN)] CHOP-like regimen for the treatment of aggressive lymphoma. The CyclOBEAP regimen was administered over a total period of 12 weeks. Doxorubicin, 50 mg/m2, was given every 2 weeks in combination with either cyclophosphamide, 1,000 mg/m2, (weeks 1, 5, 9) or etoposide, 70 mg/m2 qd ×4 (weeks 3, 7, 11). During the alternate weeks, non-myelosuppressive vincristine, 1.4 mg/m2 (maximum, 2.0 mg/ body), was given either with bleomycin, 10 mg/m2 (weeks 2, 6, 10), or alone (weeks 4,8,12). Prednisolone, 40 mg/m2, was administered daily for 14 days during weeks 1-2, 5-6, and 9-10. There were 121 eligible patients and median age of 51 years. A complete response was achieved in 106 patients (88{\%}) and a partial response in 11 patients. The 5-year overall survival (OS) rate was 72{\%} and progression-free survival (PFS) rate was 62{\%}. When the patients were divided according to the International Prognostic Index (IPI), the 5-year OS and PFS rates did not significantly differ among risk groups. When the patients with DLBCL were divided according to the IPI, the 5-year OS and PFS rates also did not significantly differ. World Health Organization (WHO) grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 13 patients. No treatment-related deaths were observed. The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma. We will perform a prospective study of CyclOBEAP regimen combined with rituximab and test its safety and efficacy.",
keywords = "Aggressive lymphoma, CyclOBEAP, Diffuse large B-cell lymphoma, International prognostic index",
author = "Nozomi Niitsu and Masataka Okamoto and Sadao Aoki and Hirokazu Okumura and Tadashi Yoshino and Ikuo Miura and Masami Hirano",
year = "2006",
month = "6",
doi = "10.1007/s00277-006-0080-x",
language = "English",
volume = "85",
pages = "374--380",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma

AU - Niitsu, Nozomi

AU - Okamoto, Masataka

AU - Aoki, Sadao

AU - Okumura, Hirokazu

AU - Yoshino, Tadashi

AU - Miura, Ikuo

AU - Hirano, Masami

PY - 2006/6

Y1 - 2006/6

N2 - Our aim was to study the efficacy of the addition of etoposide and bleomycin to a [cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisone (PDN)] CHOP-like regimen for the treatment of aggressive lymphoma. The CyclOBEAP regimen was administered over a total period of 12 weeks. Doxorubicin, 50 mg/m2, was given every 2 weeks in combination with either cyclophosphamide, 1,000 mg/m2, (weeks 1, 5, 9) or etoposide, 70 mg/m2 qd ×4 (weeks 3, 7, 11). During the alternate weeks, non-myelosuppressive vincristine, 1.4 mg/m2 (maximum, 2.0 mg/ body), was given either with bleomycin, 10 mg/m2 (weeks 2, 6, 10), or alone (weeks 4,8,12). Prednisolone, 40 mg/m2, was administered daily for 14 days during weeks 1-2, 5-6, and 9-10. There were 121 eligible patients and median age of 51 years. A complete response was achieved in 106 patients (88%) and a partial response in 11 patients. The 5-year overall survival (OS) rate was 72% and progression-free survival (PFS) rate was 62%. When the patients were divided according to the International Prognostic Index (IPI), the 5-year OS and PFS rates did not significantly differ among risk groups. When the patients with DLBCL were divided according to the IPI, the 5-year OS and PFS rates also did not significantly differ. World Health Organization (WHO) grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 13 patients. No treatment-related deaths were observed. The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma. We will perform a prospective study of CyclOBEAP regimen combined with rituximab and test its safety and efficacy.

AB - Our aim was to study the efficacy of the addition of etoposide and bleomycin to a [cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisone (PDN)] CHOP-like regimen for the treatment of aggressive lymphoma. The CyclOBEAP regimen was administered over a total period of 12 weeks. Doxorubicin, 50 mg/m2, was given every 2 weeks in combination with either cyclophosphamide, 1,000 mg/m2, (weeks 1, 5, 9) or etoposide, 70 mg/m2 qd ×4 (weeks 3, 7, 11). During the alternate weeks, non-myelosuppressive vincristine, 1.4 mg/m2 (maximum, 2.0 mg/ body), was given either with bleomycin, 10 mg/m2 (weeks 2, 6, 10), or alone (weeks 4,8,12). Prednisolone, 40 mg/m2, was administered daily for 14 days during weeks 1-2, 5-6, and 9-10. There were 121 eligible patients and median age of 51 years. A complete response was achieved in 106 patients (88%) and a partial response in 11 patients. The 5-year overall survival (OS) rate was 72% and progression-free survival (PFS) rate was 62%. When the patients were divided according to the International Prognostic Index (IPI), the 5-year OS and PFS rates did not significantly differ among risk groups. When the patients with DLBCL were divided according to the IPI, the 5-year OS and PFS rates also did not significantly differ. World Health Organization (WHO) grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 13 patients. No treatment-related deaths were observed. The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma. We will perform a prospective study of CyclOBEAP regimen combined with rituximab and test its safety and efficacy.

KW - Aggressive lymphoma

KW - CyclOBEAP

KW - Diffuse large B-cell lymphoma

KW - International prognostic index

UR - http://www.scopus.com/inward/record.url?scp=33645841342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645841342&partnerID=8YFLogxK

U2 - 10.1007/s00277-006-0080-x

DO - 10.1007/s00277-006-0080-x

M3 - Article

VL - 85

SP - 374

EP - 380

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 6

ER -